NCT01182649

Everolimus Stent in Patients With Coronary Artery Disease (CAD)

Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With Coronary Artery Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 600 (actual)
• Sponsor: San Giuseppe Moscati Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients

Detailed description

Compared with the currently available first-generation drug-eluting stents (DES), second-generation DES have been designed with the goal of improving safety and efficacy. Everolimus, a sirolimus analogue, is released from a open cell, thin-strut, cobalt-chromium frame. A significant reduction in cardiac events was noted in patients with the everolimus-eluting stent compared with those who had a paclitaxel-eluting stent. Sirolimus eluting stent was the first available drug eluting stent and is the most tested. Therefore the investigators compared the safety and efficacy of the everolimus-eluting and sirolimus eluting stents in unselected patients in real world practice.

Conditions

• Coronary Artery Disease
• Coronary Atherosclerosis

Interventions

Type	Name	Description
DEVICE	coronary stent	coronary angioplasty with stent implantation
DEVICE	stent	coronary angioplasty with stent implantation

Timeline

• Start date: 2007-03-01
• Primary completion: 2008-12-01
• Completion: 2010-06-01
• First posted: 2010-08-17
• Last updated: 2010-08-17

Locations

1 site across 1 country: Italy